Plain-English translation of NCT06046794 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing gemcitabine, a chemotherapy medication, in people with advanced pancreatic cancer that has spread to other parts of the body. The study focuses on patients who cannot tolerate a stronger chemotherapy combination called FOLFIRINOX and will receive gemcitabine instead as their first treatment. Researchers want to understand how well this medication works and whether a specific genetic signature in a patient's tumor can predict who will benefit most from this treatment.
Many pancreatic cancer patients cannot receive the standard strongest chemotherapy combination because of health conditions or other factors. This trial aims to better understand how this medication performs in these patients and whether genetic testing of their tumors can help doctors predict treatment success and personalize care.
You likely qualify if…
You likely don't qualify if…
You will receive gemcitabine chemotherapy as part of your standard cancer care at your treatment center — nothing changes about your actual treatment. What's new is that researchers will test a sample of your tumor tissue to look for a specific genetic pattern called the GemCore signature, which may help predict how well you'll respond to the medication. You'll continue with your regular follow-up visits and scans as your doctors normally schedule them, and researchers will track how your cancer responds to treatment over time.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
France